# **Blood and Circulation Module – Year 3 Semester 1**

# Duration: 03 Weeks (15 days)

|   | Concepts   | Objectives  | Activity | Time | Department                         |
|---|--|---|----------|------|------------------------------------|
| 1.  | <b>2006-3/SBM-3/01</b><br>Introduction to ischaemia, infarction, thrombosis –<br>stenosis / occlusion, embolism<br>Atherosclerosis<br>Reperfusion  | Recall<br>Objectives given in FCP   |          |      | Pathology                          |
| 3.  | <ul> <li>2006-3/SBM-3/02 Atherosclerosis <ul> <li>different patterns of atherosclerosis</li> <li>the clinical significance of atherosclerosis</li> <li>the epidemiology and risk factors of atherosclerosis</li> <li>the pathogenesis of atherosclerosis</li> <li>the macroscopic and microscopic appearances of the atheromatous plaques and fatty streaks</li> <li>Drugs</li> </ul></li></ul>  | Pathology: recall , objectives given in FCP<br>List the classes of lipid regulating drugs<br>Describe the mechanism of action,<br>pharmacokinetics and adverse effects of lipid<br>regulating drugs<br>Explain the principles involved in the selection of<br>lipid regulating drugs in clinical practice   |          | 1 Hr | Pathology<br>Pharmocology<br>(1hr) |
| Hyper<br>Pathoj<br>hypert<br>vascula<br>• mac<br>arter<br>Hyper<br>pulmon<br>• Imag | <ul> <li>2006-3/SBM-3/03         Hypertension         Pathophysiology and end organ effects of         hypertension         vascular pathology associated with hypertension         • macroscopic appearance of hyaline         arteriosclerosis and hyperplastic arteriosclerosis         Hypertensive heart disease         <ul> <li>• To be able to describe</li> <li>pathogenesis, and</li> <li>macrosopic appearance</li> <li>of heart in systemic</li> <li>hypertension</li> </ul> </li> <li>pulmonary hypertension</li> <li>• Imaging in HT</li> <li>• Drugs</li> </ul> | outline the aetiology of hypertension<br>describe the pathophysiology of hypertension.<br>describe the pathological changes in large and<br>small arteries in benign and malignant<br>hypertension.<br>outline the end organ effects due to hypertensive<br>vascular changers eg. heart, kidney, brain.<br>describe the pathological basis of the clinical<br>symptoms due to involvement of these organs<br>explain the role of imaging in hypertension.<br>list the classes of drugs used in the treatment of<br>hypertension |          | 6Hrs | Pathology (2hr)<br>Radiology(1hr)  |
|   |  | describe the mechanism of action,   |          |      | Pharmacology(2hr)                  |

|    | Nuclear Medicine imaging in cardiovascular<br>disease   | <ul> <li>pharmacokinetics, adverse effects and drug interactions of antihypertensive drugs</li> <li>Explain the principles involved in the selection of antihypertensive drugs in clinical practice</li> <li><i>To provide the student with a understanding of organ physiology and its</i></li> </ul>   |       |                             |
|----|---|--|-------|-----------------------------|
|    |   | functions with regards to radioisotope uptake in<br>health and disease by:<br>a. myocardium<br>b. renovascular system<br>correlate the radio isotope uptake with organ   |       | Nuclear Medicine<br>(1hour) |
|    |   | function in health and disease with respect to<br>a myocardium<br>b renovascular system  |       |                             |
| 5  | 2006-3/SBM-3/04<br>Metabolic Syndrome and Diabetic vascular<br>disease  | <ol> <li>describe the pathological changes in the vascular<br/>system in diabetic patients.</li> <li>describe the clinical significance of theses<br/>changes.</li> </ol>  | 1hour | Pathology (SGLA)            |
|    |   | <ol> <li>Define metabolic syndrome</li> <li>state other names given to metabolic syndrome</li> <li>list the risk factors in metabolic syndrome</li> <li>list the other conditions associated with<br/>metabolic syndrome</li> <li>state the diagnostic criteria for metabolic<br/>syndrome</li> <li>state the principles of management and<br/>prevention of metabolic syndrome</li> </ol> |       | Medicine (1hr)              |
| 6. | <ul> <li>2006-3/SBM-3/05</li> <li>Vasculitides and Raynauds disease</li> <li>pathogenesis of non-infectious vasculitidis</li> <li>the pathogenesis, macroscopic appearance of affected blood vessels in giant cell arteritis, Takayasu arteriris, polyarteritis nodosa, Kawasaki syndrome, polyangitis, Wegeners granulomatosis, thromboangitis obliterance and Raynauds disease</li> </ul> | <ol> <li>1 describe the pathogenesis of non-infectious vasculitis</li> <li>2 describe the pathological changes in vasculitis and describe the clinical outcomes due to these changes.</li> <li>3 outline the main pathological changes and clinical outcomes in the vasculitic diseases named here</li> </ol>  | 1 Hr  | Pathology                   |

| 7. | <ul> <li>2006-3/SBM-3/06<br/>Aneurysms</li> <li>define and classify aneurysms</li> <li>list the causes of aneurysm</li> <li>pathogenesis and macroscopic appearance and clinical course of abdominal aortic aneurysms</li> <li>pathogenesis and macroscopic appearnce of syphilitic aneurysms aortic dissection</li> </ul>  | <ol> <li>define the lesion aneurysm</li> <li>describe the pathogenesis of aneurysms.</li> <li>3describe different morphological types of<br/>aneurysms.</li> <li>4 describe the possible clinical outcomes and<br/>complications of aneurysms and describe their<br/>pathological basis.</li> <li>5 describe pathogenesis, morphology, clinical<br/>outcome and complications of<br/>aortic dissection.</li> </ol>   | 1 Hr | Pathology       |
|----|---|--|------|-----------------|
| 8. | <ul> <li>2006-3/SBM-3/07</li> <li>Diseases of veins and lymphatics</li> <li>the pathogenesis of thrombophlebitis and phlebothrombosis</li> <li>pathogenesis and effects of lymphangitis and lymphodema</li> </ul>   | <ol> <li>describe the pathogenesis and clinical outcomes<br/>of thromboangitis and phlebothrombosis.</li> <li>describe the pathogenesis and effects of<br/>lymphangitis and lymphoedema (recall, objectives<br/>given in FCP)</li> </ol>   | 1h   | Pathology       |
| 9. | <ul> <li>2006-3/SBM-3/08</li> <li>Ischaemic heart disease <ul> <li>epidemiology, pathogenesis of IHD</li> <li>role of fixed coronary obstructions, acute plaque change, coronary thrombus and vasoconstriction in coronary heart disease</li> <li>pathogenesis of different types of angina</li> <li>pathogenesis and macroscopic and microscopic appearance of different types of myocardial infarction</li> <li>myocardial response to coronary arterial obstruction</li> <li>the evolution of morphologic changes in myocardial infarction</li> <li>consequences and complications of myocardial infarction</li> <li>macroscopical changes of chronic ischaemic heart disease</li> </ul> </li> </ul> | <ol> <li>outline the epidemiology of IHD</li> <li>describe the pathogenesis of IHD</li> <li>describe the role of fixed coronary obstructions,<br/>acute plaque change, coronary thrombus and<br/>vasoconstriction in coronary heart disease</li> <li>describe the myocardial response to coronary<br/>arterial obstruction</li> <li>name different types of angina and describe the<br/>pathological basis of them</li> <li>describe the pathogenesis and morphogical<br/>changes in different types of myocardial<br/>infarctions.</li> <li>describe the evolution of morphologic changes<br/>in myocardial infarction</li> <li>describe the consequences and complications of</li> </ol> | 5Hrs | Pathology (2hr) |

|                     | myocardial infarction   |  |                  |
|---------------------|---|--|------------------|
|                     | 9 describe the basis and clinical significance of reperfusion injuries.   |  |                  |
|                     | 10 describe the pathological changes in chronic IHD and the clinical outcomes.  |  |                  |
| • Drugs used in IHD | List the classes of antianginal drugs   |  | Pharmacology     |
|                     | Describe the mechanism of action,<br>pharmacokinetics, adverse effects and drug<br>interactions of antianginal drugs  |  | (2hrs)           |
|                     | List the classes of antiplatelet drugs  |  |                  |
|                     | Describe the mechanism of action,<br>pharmacokinetics and adverse effects of<br>antiplatelet drugs  |  |                  |
|                     | List the oral and parenteral anticoagulants   |  |                  |
|                     | Compare and contrast unfractionated heparin and LMWHs   |  |                  |
|                     | Describe the mechanism of action,<br>pharmacokinetics, adverse effects and drug<br>interactions of oral and parenteral anticoagulants   |  |                  |
|                     | Explain the basis of monitoring anticoagulant therapy   |  |                  |
|                     | Describe the mechanism of action,<br>pharmacokinetics and adverse effects of<br>thrombolytic drugs  |  |                  |
|                     | <ol> <li>Define ischaemic heart disease</li> <li>List the risk factors for ischaemic heart disease</li> <li>List the types of ischaemic heart disease</li> <li>describe the clinical manifestations of ischaemic heart disease</li> <li>list the investigations in IHD</li> </ol> |  | Medicine (1hour) |
|                     | <ul><li>6 describe the electrophysiological changes in IHD</li><li>7 list the types of acute coronary syndrome</li><li>9 list the complications of acute coronary</li><li>syndrome</li></ul>  |  |                  |

| 10. | 2006-3/SBM-3/09<br>Valvular heart disease   | 1. describe the pathogenesis of rheumatic fever<br>and it's implications for diagnosis and   | 2Hrs | Pathology |
|-----|---|--|------|-----------|
|     | <ul> <li>valvular abnormalities caused by congenital and<br/>aquired conditions</li> </ul>  | management   |      |           |
|     | • pathogenesis and macroscopic appearance of the valves that has calcified (calcific Aortic   | 2. state the risk factors for infective endocarditis   |      |           |
|     | stenosis) and in myxomatous degeneration<br>(MVP)   | 3. describe the pathogenesis of infective endocarditis   |      |           |
|     | <ul> <li>pathogenesis, macroscopic microscopic<br/>appearances and effects of acute and chronic<br/>rheumatic heart disease</li> </ul>                                  | 4. list the important pathogens and the factors which contribute to these organisms causing infective endocarditis   |      |           |
|     | <ul> <li>pathogenesis, macroscopic microscopic<br/>appearances and effects of infective<br/>endocarditis</li> <li>conditions with non infective endocarditis</li> </ul> | 5. discuss how the pathogenesis of infective<br>endocarditis contributes to the symptoms and signs<br>of the disease and in selection of diagnostic tests. |      |           |
|     | (NBTE, Endocarditis of SLE  | 1 outline the causes of valvular heart disease   |      |           |
|     |   | 2 describe common congenital cardiac valvular abnormalities  |      |           |
|     |   | 3 describe the pathogenesis and morphological<br>changes in calcified valves (e.g. calcific Aortic<br>stenosis) and  |      |           |
|     |   | myxomatous degeneration (MVP)  |      |           |
|     |   | 4 describe the pathogenesis of rheumatic heart disease   |      |           |
|     |   | 5 describe the clinical outcomes and complications<br>of acute and chronic rheumatic heart disease and<br>describe the pathological basis of them.         |      |           |
|     |   | 6 describe the pathogenesis and pathological changes of infective endocarditis.  |      |           |
|     |   | 7 describe the pathological basis of clinical<br>outcomes and complications of infective<br>endocarditis.  |      |           |
|     |   | 8 describe the non infective causes of endocarditis.   |      |           |
|     |   |  |      |           |
|     |   |  |      |           |

| 11. | <ul> <li>2006-3/SBM-3/10<br/>Myocardial disease</li> <li>To know the causes, pathogenesis macroscopic<br/>and microscopic appearance of myocarditis</li> <li>To be able to describe the different type of<br/>cardimaopathy and macroscopic appearance of<br/>heart in these conditions.</li> <li>Tumours of the heart and blood vessels</li> </ul>  | <ol> <li>describe the pathogenesis and pathological<br/>changes of myocarditis</li> <li>describe the pathological basis of clinical<br/>outcomes and complications of myocarditis</li> <li>describe the different types of cardiomyopathies</li> <li>describe the pathological changes in these<br/>cardiomyopathies and their clinical significance.</li> <li>list the common tumours of heart and blood<br/>vessels.</li> </ol>  |                  | 1 Hr            | Pathology  |
|-----|--|--|------------------|-----------------|--|
| 12. | <ul> <li>2006-3/SBM-3/11 Pericardial disease <ul> <li>To know pathogenesis and the macroscopic appearance of pericardial effusion and haemopericardium</li> <li>To be able to describe pathological changes in the serous pericarditis, Fibrinous and serofibrinous pericarditis, Purulent or suppurative pericarditis, haemorhagic pericarditis, caseous pericarditis.</li> <li>To know the pathogenesis and macroscopic appearance of pericardium in adhesive mediastinopericarditis and constrictive pericarditis.</li> </ul></li></ul> | <ol> <li>describe the pathogenesis of pericardial effusions<br/>and haemopericardium</li> <li>describe the pathogenesis and pathological<br/>changes changes in serous pericarditis, fibrinous<br/>and serofibrinous pericarditis, purulent or<br/>suppurative pericarditis, haemorrhagic pericarditis<br/>and caseous pericarditis.</li> <li>describe the pathological basis of clinical<br/>outcomes in these conditions.</li> <li>describe the pathogenesis and pathological<br/>changes and clinical outcomes in adhesive<br/>mediastinopericarditis and constrictive pericarditis.</li> </ol> |                  | 1Hr             | Pathology  |
| 13  | 2006-3/SBM-3/12<br>Cardiac arrhythmias   | Out line the pathogenesis of cardiac arrhythmias<br>Classify the antiarrhythmic drugs<br>Describe the mechanism of action,<br>pharmacokinetics and adverse effects of<br>commonly used antiarrhythmic drugs  |                  | 1h              | Pharmacology   |
| 14. | <b>2006-3/SBM-3/13</b><br>Heart Failure (Clinicopathological correlation)  | Recall general pathology processes oedema,<br>congestion , hypertrophy and infarction.<br>describe the chest X ray manifestations of heart<br>failure.<br>List the drugs used in the treatment of heart failure<br>Describe the mechanism of action,<br>pharmacokinetics and adverse effects of drugs<br>used in the treatment of heart failure  | Staff<br>seminar | 2hrs(L)<br>SGLA | Medicine(1hrs)<br>Radiology (1/2hr)<br>Pharmacology(1/2<br>hr)<br>Discussion (1/2hrs)<br>Pathology |

| 1 Define heart failure<br>2 state the clinical features of heart failure<br>3 list the types of heart failure<br>4 state the causes of heart failure<br>5 describe the investigation of heart failure<br>6 outline the management and prevention of heart<br>failure |  |  |
|--|--|--|
|--|--|--|

#### <u>Blood & Circulation Module – (Year 3 Semester 1)</u> <u>Module Summary</u>

| Department       | Lectures (hrs) | Museum class (hrs) | SGD (hrs) | Total (hrs) |
|------------------|----------------|--------------------|-----------|-------------|
| Pathology        | 12 1/2         |                    |           | 12 1/2      |
| Pharmacology     | 5 1/2          |                    |           | 5 1/2       |
| Radiology        | 1 1/2          |                    |           | 1 1/2       |
| Nuclear Medicine | 1              |                    |           | 1           |
| Medicine         | 3              |                    |           | 3           |
| Total            | 23 1/2         |                    |           | 23 1/2      |

#### Names and the departments of the teachers involved in the teaching programme

#### **Dept. of Pathology**

Prof. N. Ratnatunga Dr S Wijetunge Dr R Waduge Dr R.Gunawardena Dr E Siriweera

## **Dept. of Pharmacology**

Dr U Dangahadeniya Dr Y Illangasekera Dept. of Medicine Prof. V.L.U.Illangasekera Dr T Jayalath

Radiology Dr. B. Hewavithana

**Dept. of Microbiology** Prof. V.Thevanesam

<u>NMU</u> Dr. J.M.C. Udugama

## **Examination Format**

| Module                                | Credits | Exam component and duration |         |      |  |
|---------------------------------------|---------|-----------------------------|---------|------|--|
|                                       |         | MCQ                         | SAQ     | Viva |  |
| Respiration and Blood and Circulation | 2.5     | 1hr                         | 1 ½ hrs |      |  |